Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 49 of 95, showing 5 Applications out of 471 total, starting on record 241, ending on 245

# Protocol No Study Title Investigator(s) & Site(s)

241.

ECCT/20/04/02   PROSYNK Study
    A 4-arm, open-label, individually randomized, controlled, phase-2, study of a probiotic and two synbiotics in young children in western Kenya.   
Principal Investigator(s)
1. Stephen Allen
Site(s) in Kenya
1. Homa Bay County Referral Hospital (Homa Bay county)
2. Siaya County Referral Hospital (Siaya county)
3. Migori County Referral Hospital (Migori county)
4. Rongo Sub-County Hospital (Migori county)
5. Rachuonyo Sub County Hospital (Homa Bay county)
6. Kendu Bay Sub-County Hospital (Homa Bay county)
7. Ahero County Hospital (Kisumu county)
8. Rabuor Sub-County Hospital (Kisumu county)
9. Akala Sub-County Hospital (Siaya county)
10. Bondo Sub-County Hospital (Siaya county)
 
View

242.

ECCT/17/03/01   The POWER cohort
    A cohort for evaluation of open-label PrEP delivery among Kenyan and South African women   
Principal Investigator(s)
1. Dr. Stella Njuguna
Site(s) in Kenya
1. Jaramogi Oginga Odinga Teaching and Referral Hospital. (Kisumu county)
 
View

243.

ECCT/22/08/02   AIM-LVRNA009-II_III-01
    A Global Multi-center, Randomized, Blinded, Placebo-controlled Phase 2/3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (LVRNA009) for the Prevention of COVID-19 in Participants Aged 18 Years and Olde   
Principal Investigator(s)
1. Bernhards Ogutu
2. Lucas Otieno
3. Videlis Nduba
4. Bernhards Ogutu
5. Jacqueline Mirera
6. Jacqueline Mirera
Site(s) in Kenya
1. Siaya Clinical Trials Unit (Siaya county)
2. Homa Bay Clinical Trials Unit (Homa Bay county)
3. Ahero Clinical Trials Unit (Kisumu county)
4. CREA-N Machakos (Machakos county)
5. CREA-N Nakuru (Nakuru county)
6. Victoria Biomedical Research Institue (Kisumu county)
 
View

244.

ECCT/21/03/01   Recombinant COVID-19 vaccine
    A global multicenter, randomized, double-blind, placebo-controlled, phase III clinical trial to evaluate the efficacy, safety, and immunogenicity of recombinant COVID-19 vaccine (Sf9 cells), for the prevention of COVID-19 in adults aged 18 years and older   
Principal Investigator(s)
1. Walter Jaoko Jaoko
Site(s) in Kenya
KAVI-institute of Clinical Research
 
View

245.

ECCT/22/03/04   VIBRI COVID-19-001/2021
    A Multi-Centre, Randomized, Double Blind, Phase 2b Trial to Evaluate the Safety and Immunogenicity of Janssen Ad26COVS1 and Novavax NVX-CoV2373 COVID-19 vaccines for Homologous and Heterologous Boosting in Adolescents and Adults Aged 12 to 64 Years with and without HIV infection in 3 African Countries (Kenya, Democratic Republic of Congo, and Rwanda).   
Principal Investigator(s)
1. Dr. Lucas Otieno Tina
Site(s) in Kenya
Victoria Biomedical Research Institute,
 
View